[go: up one dir, main page]

Wang et al., 2018 - Google Patents

Discovery of 4-[(2 R, 4 R)-4-({[1-(2, 2-Difluoro-1, 3-benzodioxol-5-yl) cyclopropyl] carbonyl} amino)-7-(difluoromethoxy)-3, 4-dihydro-2 H-chromen-2-yl] benzoic Acid …

Wang et al., 2018

View PDF
Document ID
16847272733484479947
Author
Wang X
Liu B
Searle X
Yeung C
Bogdan A
Greszler S
Singh A
Fan Y
Swensen A
Vortherms T
Balut C
Jia Y
Desino K
Gao W
Yong H
Tse C
Kym P
Publication year
Publication venue
Journal of Medicinal Chemistry

External Links

Snippet

Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that …
Continue reading at pubs.acs.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

Similar Documents

Publication Publication Date Title
Wang et al. Discovery of 4-[(2 R, 4 R)-4-({[1-(2, 2-Difluoro-1, 3-benzodioxol-5-yl) cyclopropyl] carbonyl} amino)-7-(difluoromethoxy)-3, 4-dihydro-2 H-chromen-2-yl] benzoic Acid (ABBV/GLPG-2222), a potent cystic fibrosis transmembrane conductance regulator (CFTR) corrector for the treatment of cystic fibrosis
Tang et al. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors
Breitenlechner et al. Structure-based optimization of novel azepane derivatives as PKB inhibitors
Bertrand et al. Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1–Nrf2 protein–protein interaction
Stemp et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1, 2, 3, 4-tetrahydroisoquinolin-2-yl) ethyl] cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat
Van der Plas et al. Discovery of N-(3-carbamoyl-5, 5, 7, 7-tetramethyl-5, 7-dihydro-4 H-thieno [2, 3-c] pyran-2-yl)-l H-pyrazole-5-carboxamide (GLPG1837), a novel potentiator which can open class III mutant cystic fibrosis transmembrane conductance regulator (CFTR) channels to a high extent
Li et al. Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate cancer
Owa et al. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl) amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1, 4-benzenedisulfonamide
Scanio et al. Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis
Lampe et al. Discovery of a first-in-class inhibitor of the histone methyltransferase SETD2 suitable for preclinical studies
Xiong et al. Discovery of a potent and selective fragment-like inhibitor of methyllysine reader protein spindlin 1 (SPIN1)
Shen et al. A first-in-class, highly selective and cell-active allosteric inhibitor of protein arginine methyltransferase 6
Fu et al. Discovery of highly potent and selective IRAK1 degraders to probe scaffolding functions of IRAK1 in ABC DLBCL
Bronner et al. A unique approach to design potent and selective cyclic adenosine monophosphate response element binding protein, binding protein (CBP) inhibitors
Lampe et al. Synthesis and protein kinase inhibitory activity of balanol analogues with modified benzophenone subunits
Bothe et al. Discovery of IRAK4 inhibitors BAY1834845 (zabedosertib) and BAY1830839
Das et al. Copper catalyzed one-pot three-component imination–alkynylation–aza-Michael sequence: enantio-and diastereoselective syntheses of 1, 3-disubstituted isoindolines and tetrahydroisoquinolines
Wang et al. GNE-371, a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like
Van der Plas et al. Discovery of GLPG2451, a novel once daily potentiator for the treatment of cystic fibrosis
Wilson et al. Synthesis and SAR of 1, 2, 3, 4-tetrahydroisoquinoline-based CXCR4 antagonists
Wang et al. De novo design, synthesis, and biological evaluation of 3, 4-disubstituted pyrrolidine sulfonamides as potent and selective glycine transporter 1 competitive inhibitors
Dash et al. Structure-based virtual screening identifies an 8-hydroxyquinoline as a small molecule GLI1 inhibitor
Pesci et al. Novel hits in the correction of ΔF508-cystic fibrosis transmembrane conductance regulator (CFTR) protein: synthesis, pharmacological, and ADME evaluation of tetrahydropyrido [4, 3-d] pyrimidines for the potential treatment of cystic fibrosis
Deng et al. Design, synthesis, and evaluation of dihydrobenzo [cd] indole-6-sulfonamide as TNF-α inhibitors
Giovannuzzi et al. Dual inhibitors of brain carbonic anhydrases and monoamine oxidase-B efficiently protect against amyloid-β-induced neuronal toxicity, oxidative stress, and mitochondrial dysfunction